Institute for Biomedical Ethics, University of Basel, Spalenring 73, CH-4055, Basel, Switzerland.
Institute for Biomedical Ethics, University of Basel, Bernoullistrasse 28, CH-4056, Basel, Switzerland.
Public Health. 2017 Aug;149:120-129. doi: 10.1016/j.puhe.2017.03.005. Epub 2017 Jun 6.
In the last two decades international public-private partnerships have become increasingly important to improving public health in low- and middle-income countries. Governments realize that involving the private sector in projects for financing, innovation, development, and distribution can make a valuable contribution to overcoming major health challenges. Private-public partnerships for health can generate numerous benefits but may also raise some concerns. To guide best practice for public-private partnerships for health to maximize benefits and minimize risks, the first step is to identify potential benefits, challenges, and motives. We define motives as the reasons why private partners enter partnerships with a public partner.
We conducted a systematic review of the literature using the PRISMA guidelines.
We reviewed the literature on the benefits and challenges of public-private partnerships for health in low- and middle-income countries provided by international pharmaceutical companies and other health-related companies. We provide a description of these benefits, challenges, as well as of motives of private partners to join partnerships. An approach of systematic categorization was used to conduct this research.
We identified six potential benefits, seven challenges, and three motives. Our main finding was a significant gap in the available academic literature on this subject. Further empirical research using both qualitative and quantitative approaches is required. From the limited information that is readily available, we conclude that public-private partnerships for health imply several benefits but with some noticeable and crucial limitations.
In this article, we provide a description of these benefits and challenges, discuss key themes, and conclude that empirical research is required to determine the full extent of the challenges addressed in the literature.
在过去的二十年中，国际公私合作伙伴关系对于改善中低收入国家的公共卫生变得越来越重要。各国政府意识到，让私营部门参与融资、创新、开发和分发项目，可以为克服重大健康挑战做出宝贵贡献。公私卫生合作伙伴关系可以带来诸多益处，但也可能引发一些关注。为了指导公私卫生合作伙伴关系的最佳实践，以最大限度地提高效益并将风险降至最低，首先要确定潜在的益处、挑战和动机。我们将动机定义为私营伙伴与公共伙伴合作的原因。
我们按照 PRISMA 指南对文献进行了系统回顾。
我们回顾了国际制药公司和其他与健康相关的公司提供的关于中低收入国家公私卫生合作伙伴关系的益处和挑战的文献。我们对这些益处、挑战以及私营伙伴参与合作的动机进行了描述。我们采用系统分类的方法进行了这项研究。
我们确定了六个潜在的益处、七个挑战和三个动机。我们的主要发现是，在这个主题的现有学术文献中存在显著差距。需要进一步使用定性和定量方法进行实证研究。根据现有有限的信息，我们得出结论，公私卫生合作伙伴关系带来了一些益处，但也存在一些明显而关键的局限性。
在本文中，我们对这些益处和挑战进行了描述，讨论了关键主题，并得出结论，需要进行实证研究，以确定文献中所解决的挑战的全部程度。
